Drug Trial News

RSS

Rexahn submits Phase IIb protocol to FDA for study of Serdaxin for major depressive disorder

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that it has submitted a Phase IIb protocol to the U.S. Food and Drug Administration (FDA) for the clinical study of Serdaxin for the treatment of major depressive disorder (MDD).

7 Sep 2010

CytRx commences PROACT Phase 2 clinical trial of bafetinib for advanced prostate cancer

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced initiation of the PROstate Advanced Cancer Treatment (PROACT) Phase 2 proof-of-concept clinical trial to evaluate the efficacy and safety of bafetinib in patients with advanced prostate cancer.

7 Sep 2010

Promedior initiates PRM-151 Phase 2a clinical study in prevention of scarring post glaucoma filtration surgery

Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic and inflammatory diseases, announced today that it has initiated a Phase 2a clinical study of PRM-151 to evaluate the efficacy, safety, and tolerability of PRM-151 in preventing post-surgical scarring in glaucoma patients following glaucoma filtration surgery. There currently are no approved drugs for preventing post-surgical scarring in glaucoma, and there are no approved anti-fibrotic drug therapies in the U.S. or Europe for any fibrotic disease.

7 Sep 2010

Positive immune responses elicited from Scancell's DNA vaccine in combination with ImmuneRegen's Homspera

Scancell Holdings Plc, the developer of therapeutic cancer vaccines, announces that a treatment utilising a DNA vaccine based on its ImmunoBody® technology, in combination with ImmuneRegen BioSciences, Inc.®'s lead compound, Homspera®, has significantly improved the immune response of the vaccine in an animal model. Follow-up studies are currently being performed to optimize the effects of Homspera in enhancing the next generation of Scancell's cancer vaccines.

7 Sep 2010

TenX Biopharma recommences enrollment in suspended Phase III trial for cutaneous T-cell lymphoma

TenX Biopharma, Inc. announced today that it has re-initiated enrollment in the pivotal Phase III clinical trial assessing zanolimumab treatment for cutaneous T-cell lymphoma (CTCL) patients (ClinicalTrials.gov identifier: NCT00127881). The trial enrollment was suspended in October 2008 while Genmab was seeking a out-license agreement to further develop the compound. TenX Biopharma acquired global rights to zanolimumab in February, 2010 from Genmab.

7 Sep 2010

Hallucinogen psilocybin safe for administration in patients with advanced-stage cancer and anxiety: Study

A pilot study suggests the hallucinogen psilocybin may be feasible and safe to administer to patients with advanced-stage cancer and anxiety, with promising effects on mood, according to a report published online today that will appear in the January 2011 print issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

7 Sep 2010

Axelar AB publishes first AXL1717 data on phase I/II cancer study

Axelar AB today announces that the first submitted medical article on the ongoing phase I/II cancer study with AXL1717 has been published in Acta Oncologica.

7 Sep 2010

Microplasmin MIVI-TRUST Phase III program's positive pooled results presented at EURETINA

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, cardiovascular disease and cancer, announces that the pooled results from the successful microplasmin MIVI-TRUST Phase III program were presented today at the EURETINA (European Society of Retina Specialists) Congress in Paris, France.

6 Sep 2010

AVAC calls for economic and political support for CAPRISA 004 microbicide trial's critical follow-up studies

AVAC today issues a call to action to donors, policy-makers, researchers and advocates to ensure that critical follow-up studies to the landmark CAPRISA 004 microbicide trial receive the economic and political support needed to move forward as quickly as possible. The call comes as a group of microbicide and public health experts have agreed upon a plan for further studies, which are expected to cost $100 million over three years, of which only $58 million has been committed.

4 Sep 2010

Researchers complete INX-189 clinical trials for Hepatitis C virus

The first clinical trials on a new investigational drug being developed to treat infections caused by Hepatitis C virus have been successfully completed.

3 Sep 2010

ImmunoCellular Therapeutics updates accomplishments in Letter to Shareholders

As the summer comes to a close, I wanted to update you on the Company's accomplishments this year, which set the stage for an exciting fall. The first eight months of the year have been very successful, with the Company attaining many of its goals, despite a very difficult economic environment, which has created challenges for many small biotechnology companies. Today, IMUC is in its best financial position ever and well positioned to validate the success it achieved in a Phase I trial for ICT-107, its dendritic cell-based cancer vaccine product candidate.

3 Sep 2010

Data from ESC confirms reduction in adverse events with CYPHER Stent

Additional Analysis of 18 Month Data of the SORT OUT III Trial Provides Detail on Safety and Efficacy Outcomes in Patients With Diabetes, Acute Coronary Syndrome, or Treatment of Multiple Lesions

3 Sep 2010

GOG to conduct Phase II trial on primary peritoneal cancer

Oncolytics Biotech Inc. announced today that the Gynecologic Oncology Group (GOG) intends to conduct a randomized Phase II trial of weekly paclitaxel versus weekly paclitaxel with REOLYSIN(R) in patients with persistent or recurrent, ovarian, fallopian tube or primary peritoneal cancer (GOG186H).

3 Sep 2010

Gilead Sciences seeks MAA in Europe for fixed-dose combination of Truvada and TMC278 for HIV-1 infection

Gilead Sciences, Inc. today announced that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for marketing approval for the fixed-dose combination of Truvada® (emtricitabine and tenofovir disoproxil (as fumarate)) and Tibotec Pharmaceuticals' investigational non-nucleoside reverse transcriptase inhibitor TMC278 (rilpivirine (as hydrochloride)) for the treatment of HIV-1 infection in adults.

3 Sep 2010

Iroko Cardio International Sàrl announces data on HDB dosing of tirofiban, abciximab in interventional cardiology

Iroko Cardio International Sàrl announces long-term, three-year, mortality data from the Phase III, open label, multi-national study comparing high-dose bolus (HDB) dosing of AGGRASTAT(tirofiban) (25mcg/kg bolus followed by a 0.15mcg/kg/min infusion for 18-24 hours) vs. ReoPro (abciximab) in patients undergoing primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI), presented at the 2010 European Society of Cardiology Meeting in Stockholm, Sweden.

3 Sep 2010

Seattle Genetics achieves milestone on Agensys' initiation of AGS-16M8F ADC phase I trial for cancer

Seattle Genetics, Inc. announced today that it has achieved a milestone under its antibody-drug conjugate (ADC) collaboration with Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc. The milestone was triggered by Agensys' initiation of a phase I trial for AGS-16M8F, an ADC for the treatment of cancer utilizing Seattle Genetics' technology.

3 Sep 2010

Santhera, Ipsen partner to develop and commercialize fipamezole outside North America and Japan

Santhera Pharmaceuticals and Ipsen today announced a license agreement for the development and commercialization of fipamezole (antagonist of the adrenergic alpha-2 receptor) for territories outside of North America and Japan. This first-in-class compound is currently under investigation for the treatment of levodopa-induced dyskinesia in Parkinson's Disease.

3 Sep 2010

Transdel Pharmaceuticals presents Ketotransdel Phase 3 data at 13th World Pain Congress

Transdel Pharmaceuticals, Inc., a specialty pharmaceutical company focused on developing topically administered products using its proprietary transdermal delivery platform, announced today the final data set from its Phase 3 study of Ketotransdel® (TDLP-110) at the 13th World Congress on Pain in Montreal, Canada.

2 Sep 2010

Halozyme initiates Ultrafast Insulin combination Phase 2 studies with rHuPH20

Halozyme Therapeutics, Inc. today announced the initiation of two Phase 2 Ultrafast Insulin treatment studies that utilize its rHuPH20 hyaluronidase enzyme (PH20) in combination with the two leading commercially available mealtime analogs: insulin aspart, the active ingredient in NovoLog®, and insulin lispro, the active ingredient in Humalog®.

2 Sep 2010

Lytix Biopharma granted Hungarian approval for Lytixar Phase IIa clinical trial in Gram positive skin infections

The Norwegian pharmaceutical company Lytix Biopharma AS today announces the approval in Hungary to commence a Phase IIa clinical trial with Lytixar (LTX-109) treatment of skin infections caused by Gram positive bacteria.

2 Sep 2010

Drug Trial News

Rexahn submits Phase IIb protocol to FDA for study of Serdaxin for major depressive disorder

CytRx commences PROACT Phase 2 clinical trial of bafetinib for advanced prostate cancer

Promedior initiates PRM-151 Phase 2a clinical study in prevention of scarring post glaucoma filtration surgery

Positive immune responses elicited from Scancell's DNA vaccine in combination with ImmuneRegen's Homspera

TenX Biopharma recommences enrollment in suspended Phase III trial for cutaneous T-cell lymphoma

Hallucinogen psilocybin safe for administration in patients with advanced-stage cancer and anxiety: Study

Axelar AB publishes first AXL1717 data on phase I/II cancer study

Microplasmin MIVI-TRUST Phase III program's positive pooled results presented at EURETINA

AVAC calls for economic and political support for CAPRISA 004 microbicide trial's critical follow-up studies

Researchers complete INX-189 clinical trials for Hepatitis C virus

ImmunoCellular Therapeutics updates accomplishments in Letter to Shareholders

Data from ESC confirms reduction in adverse events with CYPHER Stent

GOG to conduct Phase II trial on primary peritoneal cancer

Gilead Sciences seeks MAA in Europe for fixed-dose combination of Truvada and TMC278 for HIV-1 infection

Iroko Cardio International Sàrl announces data on HDB dosing of tirofiban, abciximab in interventional cardiology

Seattle Genetics achieves milestone on Agensys' initiation of AGS-16M8F ADC phase I trial for cancer

Santhera, Ipsen partner to develop and commercialize fipamezole outside North America and Japan

Transdel Pharmaceuticals presents Ketotransdel Phase 3 data at 13th World Pain Congress

Halozyme initiates Ultrafast Insulin combination Phase 2 studies with rHuPH20

Lytix Biopharma granted Hungarian approval for Lytixar Phase IIa clinical trial in Gram positive skin infections

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News